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Summary.-Sadler and Castro (1976) reported that a single dose of C. parvum vaccine
given i.p. or i.v. to mice 4 days before excision of subcutaneous transplants of Lewis
lung carcinoma significantly reducedthe incidence oflung metastases in the operated
mice. In similarly designed experiments, using2 different carcinomas ofspontaneous
origin in our owninbred mouse colonies, we were unableto demonstrate anyinfluence
of C. parvum vaccine onthe incidence or latent period ofsecondary disease inoperated
mice. We discuss possible reasons for our failure to reproduce the findings of Sadler
and Castro.
SADLER AND CASTRO (1976) reported
that a single dose of C. parvum vaccine
given i.p. or i.v. before excision of sub-
cutaneous transplants of Lewis lung
carcinoma in C57 BL mice (the strain of
origin) significantly reduced the incidence
of lung metastases 21 days after trans-
plantation of tumour. The vaccine was
most effective when given 3-4 days before
operation. Since Lewis lung carcinoma
arose as long ago as 1951, it was possible
that the effectiveness of the vaccine using
this system had depended upon a minor
degree of artefactual tumour immuno-
genicity imposed by genetic divergence
between the mouse in which the tumour
arose and the recipient mice used by
Sadler and Castro (1976). These authors
suggested to us that it would be ofinterest
to attempt to reproduce their findings in
simulated experiments using transplanted
tumour systems, available to us, in which
the intromission of artefactual tumour
immunogenicity is far less likely. The
variety ofsites and the wide range oftime
in which secondary disease was manifested
using our systems made the presentation
of our data necessarily more complex than
that possible for Sadler and Castro (1976).
Nevertheless, we believe that our assess-
ment ofthe incidence ofsecondary disease
has been sufficiently comprehensive to
allow equal consideration of our data as
evidence bearing on the general question
whether preoperative administration of C.
parvum vaccine can reduce or delay the
development of secondary disease.
MATERIALS AND METHODS
Mice and tumours.-CBA Carcinoma NT
(Hewitt) is a poorly differentiated adeno-
carcinoma which arose spontaneously in 1968
in a female ofour colony ofCBA/Ht mice. We
have previously published data for the sites
and times of manifestation of secondary
disease in mice which had had intradermal
transplants of this tumour excised (Hewitt,
1976; Hewitt and Blake, 1977a).
WHT Carcinoma N-C (Hewitt) is a
moderately well-differentiated adeno-
carcinoma which arose spontaneously in a
female of our colony of WHT/Ht mice in
1974.
Both tumours arose in subcutaneous sites,
and may be assumed to be of mammary
origin; they have been maintained by serial
s.c. transplantation in mice of the strain of
origin, and in the present experiments were
transplanted to 2-4-month-old females. FromH. B. HEWITT AND E. R. BLAKE
the results of putative, specific, active-
immunization studies, usingfully quantitative
challenge assays for testing "immunized"
mice, we have shown that neither tumour is
immunogenic in the mouse strain of origin.
Transplantation and excision of tumours.-
Suspensions of viable tumour cells were pre-
pared from solid tumours by multiple succes-
sive digestions oftumour mince using trypsin
and pancreatin (Hewitt, 1966); the larger
clumps of cells remaining after digestion were
allowed to fall out ofthe suspensions during a
short period of sedimentation under gravity.
The density ofmorphologically intact tumour
cells in the supernate was determined by
counting under phase-contrast microscopy
and expressed as cells per 20 mm3. Batches of
mice to receive transplanted tumours were
injected with a specified number of tumour
cells in 20 mm3 ofTyrode solution containing
5% mouse serum. Injections were given intra-
dermally (i.d.) under ether anaesthesia in a
site near the costal margin in the anterior
axillary line on the left side. The resulting
tumours were simply excised under ether
anaesthesia by removing an ellipse of skin
bearing the tumour and extending 2-4 mm
beyond it; wounds were closed with 3 metal
clips which were removed 5-6 days later.
Excised tumours were weighed individually
after trimming away the margin of free skin.
Corynebacterium parvum vaccine.-Miceto
receive vaccine were injected i.p. with 0.1 ml
of "Coparvax" (Wellcome Reagents Ltd) 4
days before excision of tumours, this being
the optimum time for effectiveness of the
vaccine in the experiments of Sadler and
Castro (1976). In a preliminary study of the
effect of this dose of vaccine on normal mice,
we observed that the mice remained hunched
and quiet for some hours after injection; slight
lymphopenia and anaemia were evident by
the 10th day; marked splenomegaly and
hepatomegaly were present on the 21st day,
and had not entirely resolved by the 77th
day.
Assessment of secondary disease in operated
mice.-Mice were examined every 2-3 days
after operation. Recurrence near the site of
excision, and regional nodal metastasis in the
axilla, were detected by palpation, and mice
were killed and dissected within the next few
days, after progressive growth of tumour in
these sites had been confirmed; a record was
made of the number of metastatic nodules
visible on the surface of the lungs and of the
presence of metastasis in any other viscera
(although individual nodules were counted on
lungs, metastasis in other organs was recorded
as oneforeachorganaffected). Micewhosefirst
manifestation ofsecondary disease was due to
visceral metastasis, presented with slight
general sickness; these were killed and dis-
sected at the first signs of sickness, and the
total number of metastases was recorded as
above. Although this mode ofassessment gave
a spread of times after operation at which
counts were made, we have accounted this in
our results by recording the mean times of
examination for the vaccinated and un-
vaccinated groups ofmice in each experiment.
EXPERIMENTS AND RESULTS
CBA Carcinoma NT
All mice of a batch of 40 which had
received single i.d. inocula of 56,000 viable
tumours cells on Day 0 had developed
tumours by Day 17, and on this day they
were segregated into 2 equal groups; one
group received C. parvum vaccine i.p.
and the other received no injection. On
Day 21, 4 days after vaccination, mice of
both groups had their tumours excised,
after which they were observed for mani-
festations ofsecondary disease. One mouse
of each group was lost during anaesthesia.
The experiment was terminated on Day
123, 48 days after the last mouse presented
with signs of disease. Surviving mice were
killed and found to be free from macro-
scopic signs of disease.
The results of the experiment are
TABLE I.-Comparative data for develop-
ment of secondary disease in tumour-
excised mice which did or did not receive
C. parvum vaccine before surgery. CBA
Carcinoma NT
No. of mice
Mean tumour mass (mg)
Local recurrences
Nodal metastases
Visceral metastases
Mean metastases/mouse
Mean days to necropsy
Survival rate at 123 days
Un-
vaccinated Vaccinated
19 19
149 ±74
4 (39+4)*
1 (45)*
8 (72±13)*
4+4
61± 18
6/19
107±67
2 (32±1)*
4 (49±14)*
10 (72± 12)*
4±4
63±16
3/19
* In parentheses, mean day of presentation + s.d.
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recorded in Table I, which shows that,
although the mean weight of the excised
tumours was smallerinthevaccinatedthan
in the unvaccinated mice, there was no
significant difference between the 2 groups
in respect of: the incidence or mean time
of presentation at any of the different
sites of secondary disease; the mean
number of metastases per mouse; or the
mean time at which the mice were killed
and the counts made. Fewer of the
vaccinated than of the unvaccinated mice
survived without disease to the end ofthe
period ofobservation, but this difference is
not significant. Additionally, we have
comparedtheincidences andlatentperiods
ofthe 3 forms ofpresentation ofsecondary
disease in the vaccinated mice with the
corresponding pooled values for 193 un-
vaccinated, operated mice observed in
previous metastasis studies ofthis tumour
(Hewitt and Blake, 1977a). There was no
significant difference for any ofthe values.
We conclude thatpre-surgical treatment
ofthe mice with C. parvum vaccine had no
influence on the development ofsecondary
disease from this tumour.
WHT Carcinoma N-C
A batch of 38 WHT mice received single
i.d. inocula in the left flank of 220,000
tumour cells on Day 0. On Day 12, by
which time all mice had developed dermal
tumours, they were allocated to 2 equal
groups, one of which received i.p. a single
injection of 0-1 ml of C. parvum vaccine.
TABLE II.-Comparative data for develop-
ment of secondary disease in tumour-
excised mice which did or did not receive
C. parvum vaccine before surgery. WHT
Carcinoma N-C
Un-
vaccinated Vaccinated
No. of mice 18 19
Mean tumour mass (mg) 172±30 155±30
Local recurrences 12 (33±3)* 7 (34±7)*
Nodal metastases 6 (35±4)* 9 (45±12)*
Visceral metastases 2 (45±6)* 0
Mean metastases/mouse 1*9±1-9 1-7±2 *3
Mean days to autopsy 42 ±8 46± 11
Survival rate at 72 days 1/18 3/19
* In parentheses, mean day of presentation±s.d.
On Day 16, 4 days after vaccination, all
mice of both groups had their tumours
excised, and were subsequently observed
for development ofsecondary disease. The
results of the experiment are given in
Table II, in the same form as for the
similar experiment with the CBA car-
cinoma. It is seen that there is no signifi-
cant difference in the incidence or mean
time of presentation of the various cate-
gories of secondary disease, in the mean
number ofmetastases per mouse, or in the
survival rate at the end ofthe observation
period. One mouse of the unvaccinated
group died under anaesthesia during the
operation for excision.
Thus, the results of the experiments
using the 2 carcinomas failed to reveal any
influence of the single dose of C. parvum
vaccine on the course ofsecondary disease.
We have thus been unable to confirm the
results of Sadler and Castro (1976), who
used the Lewis lung carcinoma, although
we had imitated their conditions as
closely as the intrinsic differences between
the tumour systems allowed.
DISCUSSION
Our failure to demonstrate that C.
parvum vaccine given before excision of
tumours had a restraining influence on the
development of secondary disease in the
operatedmiceconformstoourexpectations
for tumours ofthe status ofthose used.We
have reported elsewhere (Hewitt et al.,
1976) that we were unable to demonstrate
immunogenicity in any of 7 transplanted
murine tumours we have examined. Mice
were subjected to putative, specific, active
immunization by multiple injections of
lethallyirradiated cells. Viablehomologous
tumour cells were then assayed in parallel
in the putatively immunized and in un-
treated mice. The number of viable
tumour cells required to give rise to
tumours in 50% of mice was in no case
higher in the immunized than in the un-
treated mice. We attribute our uniform
failure to demonstrate immunogenicity to
the status of the systems we have in-
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variably used; allhavebeenofspontaneous
origin in our own inbred colonies of mice
and have been isogeneically transplanted
within the same colonies.
Since C. parvum vaccine, used in relation
to tumours, is considered to be a non-
specific stimulator (or moderator) of
immune responsiveness, there is no reason
to believe that it would have an effect on
transplanted systems in which immuno-
genicity cannot be demonstrated by
specific immunization. We are not aware
of any evidence that the bacteria can
superimpose specific antigenicity on
tumour cells.
The most likely explanation for our
failure to confirm the findings of Sadler
and Castro (1976) lies in the comparative
status ofthe transplanted tumour systems
used, in respect of their liability to super-
imposed artefactual immunogenicity. Al-
though the Lewis lung carcinoma is of
spontaneous origin, its 25-year history of
transplantation and inter-laboratory
transfer imply that any contemporary
transplant system by which it is repre-
sented has been exposed to very large
opportunities for the acquisition of arte-
factual immunogenicity. We refer not only
to the considerable risk ofgenetic diversity
between the substrain of origin (C57BL)
and the recipients used by Sadler and
Castro (C57BL/10 Sc Sn) but to the risk of
contamination of the tumour by onco-
viruses or non-oncogenic viruses, in one or
more of the laboratories in which the tu-
mour has resided. It is known that such
accidental infection can confer permanent
immunogenicity on atissue (independently
ofthe survival ofinfective virus init) when
it is transplanted to nominally isogeneic
mice not tolerant to the infective agent
(Svet-Moldavsky et al., 1970; Fieldsteel et
al., 1973; Kobayashi et al., 1969). The
systems we have used here are only 10
and 4 years from their times of origin and
have been maintained in a laboratory to
which no viruses have been deliberately
imported.
Our systems are distinguished from the
Lewis lung carcinoma system by their
multiform expression ofsecondary disease.
Whereas only pulmonary metastases were
observed in the experiments of Sadler and
Castro (1976), we encountered significant
incidences of nodal metastasis and local
recurrence in our operated mice. The
relatively high incidences of local re-
currence (16% for the CBA tumour and
51% for the WHT tumour) are not in our
view the reflection of inadequate surgery,
in the sense of excision through tumour.
The margin oftumour-free skinwas always
generous and we have encountered a high
rate of recurrence even when very early
dermal tumours have been excised excep-
tionally widely. For the following reasons
we believe that our recurrences arise from
tumour cells which have been disseminated
into lymphatics: we haveshownpreviously
(Hewitt and Blake, 1977b) that, in the case
of all of 6 tumours investigated, there is a
continuous flow of viable tumour cells
through the regional nodes; our re-
currences were nearly all sited at or beyond
the cephalic end of our longitudinal
elliptical incisions, in a direction towards
the regional (axillary) nodes; in un-
published experiments with CBA Car-
cinomaNT we have observed thattumours
commonly arise at the siteoftightligatures
inserted between the tumours and the
axillary nodes during tumour growth. Our
conclusion is that the effect of surgery is
either to release tumour cells from lym-
phatics at the site of their transection, or
to produce stasis of lymphatic flow (with
encouragement of endothelial adherence
and growth of tumour cells) beyond the
wound. A similar explanation is commonly
given for the high recurrence rate after
local excision of clinical malignant
melanomas.
Sadler and Castro (1976) have suggested
that their experimental results may have
some clinical application in the "therapy"
of cancer patients who have undergone
surgery, but our findings discourage such
application, especially as our assessments
have taken account of all the usual mani-
festations of secondary disease.
It is questioned here whether the general
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bodyofevidencefromexperimental studies
of the effect of C. parvum vaccine on
animal tumours justifies the 70 or more
registered clinical trials of this form of
immunotherapy which are in progress or
projected (Compendium of Tumor Im-
munotherapy Protocols, August, 1976).
An analysis of 46 animal tumour systems
used for studies of C. parvum vaccine,
reported in 28 randomly selected papers
published inthe period 1972-1975 (Hewvitt,
1978) revealed that: 78% of the tumours
had been induced by powerful chemical
carcinogens, oncogenicvirusesorradiation,
7% were allografted, and 4% had been
initiated or maintained in tissue culture;
of the residual spontaneously originated,
uncultured, tumours used, all were over
20 years from their origin. These are all
conditions of origin or maintenance which
carry a high risk of the imposition of
artefactual immunogenicity on a trans-
planted tumour system. Thus, no tumour
in the sample can be accorded high status
as a model of spontaneous endogenous
cancer in man. It is our view that, in as
much as clinical trials ofC. parvum vaccine
may be considered to require clear pre-
liminary evidence ofthe therapeutic value
of C. parvum vaccine from animal tumour
studies employing impeccable models,
these trials are premature.
The experiments reported were suggested to us by
Mr J. E. Castro, and we are grateful to him and to
his collaborator, Dr T. E. Sadler, for their interest
and advice. We are specially grateful to Professor
E. A. Wright, for his warm encouragement and for
the facilities he provided to us. We are indebted to
Miss Angela Walder and Miss Carol Dear for having
first isolated the spontaneous tumours used, and to
Miss Patricia Ashley and Mr R. Thatcher, for breed-
ing and care ofthe mice. The research was supported
by a generous grant from the Cancer Research
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